Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00761631 · ClinicalTrials.gov registry record · Phase 3

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

A Phase 3 study of Healthy Subjects, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
1,200
Enrollment target
20
Study locations

NCT00761631 is a Phase 3 study of Healthy Subjects that has completed, run by Pfizer. The registered enrollment target is 1,200 participants, above the 111-participant average among 69 other Healthy Subjects trials with a reported enrollment target (981% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00761631, a Phase 3 study of Healthy Subjects, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
1,200 participants
Enrollment target
20
Study locations

Study Summary

This open-label, multicenter study is designed to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy children aged more than 15 months up to less than 18 years.

Conditions Studied

Healthy Subjects

Interventions

  • BIOLOGICAL 13 valent pneumococcal conjugate vaccine

Study Locations (20)

Arkansas

  • Pfizer Investigational Site - Benton
  • Pfizer Investigational Site - Fayetteville
  • Pfizer Investigational Site - Jonesboro
  • Pfizer Investigational Site - Little Rock

California

  • Pfizer Investigational Site - Fountain Valley
  • Pfizer Investigational Site - Loma Linda
  • Pfizer Investigational Site - Torrance

North Dakota

  • Pfizer Investigational Site - Bismarck
  • Pfizer Investigational Site - Fargo

Ohio

  • Pfizer Investigational Site - Cincinnati
  • Pfizer Investigational Site - Cleveland

Florida

  • Pfizer Investigational Site - Tampa

Georgia

  • Pfizer Investigational Site - Marietta

Illinois

  • Pfizer Investigational Site - DeKalb

Kentucky

  • Pfizer Investigational Site - Louisville

Trial Details

FieldValue
Enrollment Target 1,200 participants
Start Date 2008-12
Est. Completion 2010-07
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00761631

The ClinicalTrials.gov registry entry for NCT00761631 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 111-participant average among 69 other Healthy Subjects trials with a reported enrollment target (981% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 1 intervention - of which 13 valent pneumococcal conjugate vaccine is the first listed.

NCT00761631 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Arkansas, California, North Dakota.

Frequently Asked Questions

What is clinical trial NCT00761631 about?

NCT00761631 is a clinical study titled "Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years". This open-label, multicenter study is designed to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy children aged more than 15 months up to less than 18 years.

What is the current status of trial NCT00761631?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2008-12. Estimated completion is 2010-07.

What conditions does trial NCT00761631 study?

This clinical trial studies the following conditions: Healthy Subjects.

What interventions are being tested in trial NCT00761631?

The interventions under investigation include: 13 valent pneumococcal conjugate vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00761631?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00761631 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy Subjects

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy Subjects

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.